Cervavac: First indigenously developed Human Papillomavirus Vaccine

On 1st September, 2022, the government announced the scientific completion of Cervavac, India’s first indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for the prevention of cervical cancer.

About Cervavac

  • Cervavac is developed by the Pune-based Serum Institute of India in coordination with the Government of India’s Department of Biotechnology (DBT).

Effectiveness

  • HPV vaccines are given in two doses and data has shown that the antibodies that develop after both are administered can last up to six or seven years.
  • The HPV vaccine protects the body against the human papillomavirus (HPV), which can cause vaginal, vulvar, anal and oral cancers, besides cervical ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Buy October 2022 Issue

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Related Content

Science & Technology